| Authors: |
Manzi S; Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania., Bruce IN; Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.; Centre for Public Health, Faculty of Medicine, Health, and Life Sciences, Queen's University Belfast, Belfast, United Kingdom., Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia., Furie R; Division of Rheumatology, Northwell, Great Neck, New York., Tanaka Y; Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan., Kalunian KC; Lupus Center of Excellence, Division of Rheumatology, Autoimmunity, and Inflammation, University of California, San Diego School of Medicine, La Jolla, California., Askanase A; Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York., Puzio P; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland., Khan E; BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom., Wissmar J; BioPharmaceuticals R&D, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden., Song M; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, Massachusetts., Lindholm C; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden. |
